Explore the clinical performance insights of Aiosyn Mitosis Breast at USCAP 2024

By Victoria Grosu
21 March, 2024

Aiosyn, a pioneering medical software company specializing in AI-powered pathology solutions for cancer and kidney diseases, recently conducted a clinical performance study in collaboration with Radboud university medical center. The study, aimed at evaluating the benefits offered by Aiosyn Mitosis Breast within the pathology practice, will be presented during the 113th USCAP Annual Meeting.

Aiosyn Mitosis Breast is an innovative algorithm designed to assist pathologists in counting mitoses in breast biopsies and resections. This critical task plays a pivotal role in assessing tumor proliferation rates and contributes to cancer grading. By harnessing the power of artificial intelligence, Aiosyn aims to enhance efficiency and consistency in this labor-intensive process subject to observer variability.

Leslie Tessier, a PhD Candidate from the Computational Pathology Group at Radboudumc, will present on March 25th (pitch at 15:53) the poster featuring the clinical performance study of Aiosyn Mitosis Breast (poster number 328). The study involved 28 pathologists from 9 countries and demonstrated significant improvements in efficiency and consistency among pathologists when utilizing Aiosyn Mitosis Breast.

Join us in Baltimore to learn more! Be sure not to miss Leslie’s poster pitch, and swing by our booth, #1148, for an exclusive demonstration of Aiosyn Mitosis Breast and other cutting-edge precision pathology solutions. In addition to our AI-powered mitosis detection, explore our automated quality control and kidney image analysis services, which have the potential to shape the future of drug development and diagnostics.

Please send an email to [email protected] to schedule a meeting with our team.